Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study
Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study
Yongli Hua, Xuanxuan Wang, Shaoyuan Shi, Li Zhou et al.
Citations
5 citations
Journal
Frontiers in Medicine
Topics
Hepatitis B Virus Studies
Field-Weighted Citation Impact (FWCI)
1.93
article
Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study